Does previous use of tumour necrosis inhibitors change the therapeutic effect of interleukin ( IL )‐17 or IL ‐12/23 inhibitors on psoriasis and psoriatic arthritis? Results of a systematic review

Clinical and Experimental DermatologyAccepted Articles REVIEW ARTICLE Would previous use of TNF inhibitors affect the therapeutic effect of IL-17 or IL-12/23 inhibitors on psoriasis and psoriatic arthritis: results from a systematic review Yan Xie, Corresponding Author Yan Xie xy490219245@126.com orcid.org/0000-0001-8987-4844 Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, ChinaCorrespondence: Yan Xie E-mail: xy490219245@126.comSearch for more papers by this authorYang Liu, Yang Liu Tsinghua Clinical Research Institute (TCRI), School of Medicine, Tsinghua University, Beijing, ChinaSearch for more papers by this author Yan Xie, Corresponding Author Yan Xie xy490219245@126.com orcid.org/0000-0001-8987-4844 Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, ChinaCorrespondence: Yan Xie E-mail: xy490219245@126.comSearch for more papers by this authorYang Liu, Yang Liu Tsinghua Clinical Research Institute (TCRI), School of Medicine, Tsinghua University, Beijing, ChinaSearch for more papers by this author First published: 24 April 2022 https://doi.org/10.1111/ced.15237 This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi:10.1111/ced.15237 AboutPDF ToolsExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Summary Objectives To investigate the therapeutic effect of interleukin (IL)-17 and IL-12/23 inhibitors in Psoriatic arthritis (PsA) or psoriasis patients who were intolerant or responded inadequately to tumor necrosis factor (TNF) inhibitors (TNFi-experienced). Methods A systematic review of randomized controlled trials searched from the Pubmed, Cochrane Library, and Embase was conducted on May 17, 2021. Psoriasis Area and Severity Index (PASI) responses (PASI75/90), the American College of Rheumatology (ACR) response criteria (ACR20/50/70), and full resolution of dactylitis/enthesitis were used to assess the treatment efficiency. Results A total of 7 studies with 3398 PsA patients were included, 1330 of whom were intolerant or responded inadequately to TNFi. All studies were categorized as low risk of bias. For IL-17A inhibitors, significant higher achievements in all of the endpoints were observed when comparing with placebo. However, the proportions of patients achieving these endpoints were lower in TNFi-experienced patients when compared with that in TNFi-naïve patients. However, the differences between TNFi-naïve and TNFi-experienced patients were only significant for ACR responses and full resolution of enthesitis. As for IL-12/23 inhibitors, only results of ACR20 response were reported. And significantly more TNFi-experienced patients achieved ACR 20 response when compared to that receiving placebo. The differences in treatment efficacy between TNFi-experienced patients and TFNi-naïve patients was not significant. Conclusions IL-17A and IL-12/23 inhibitors were still efficient for PsA or psoriasis patients who were TNFi-failed or intolerant. However, the efficacy was lower than that in TNFi-naïve patients. And more studies are warranted to elucidate relevant problems. Supporting Information Filename Description ced15237-sup-0001-Supinfo.docxWord 2007 document , 4.9 MB Supplementary Material Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. Accepted ArticlesAccepted, unedited articles published online and citable. The final edited and typeset version of record will appear in the future. RelatedInformation